TABLE 2.
Comparison of clinical features between ovarian endometriosis with KRAS p.G12V mutant allele expression and KRAS wild‐type
| Characteristics | KRAS p.G12V (10) | KRAS wild‐type (5) | P‐value |
|---|---|---|---|
| Age at operation(SD) a | 43.1 (7.0) | 44.8 (4.3) | .533 |
| Parity b | 4/10 (40.0%) | 1/5 (20.0%) | .600 |
| Null para | 6/10 (60.0%) | 4/5 (80.0%) | |
| Multi para | 4/10 (40.0%) | 1/5 (20.0%) | |
| Preoperative treatment b | 1/10 (10.0%) | 2/5 (40.0%) | .537 |
| DNG | 1/10 (10.0%) | 1/5 (20.0%) | |
| GnRHa | 0/10 (0.0%) | 1/5 (20.0%) | |
| Pre‐operation CA125 (U/mL) a | 119.6 ± 69.0 | 56.0 ± 67.0 | .240 |
| Tumor size (mm) a | 61.8 ± 20.1 | 60.2 ± 30.0 | .972 |
| Laterality b | .231 | ||
| Unilateral | 6/10 (60.0%) | 5/5 (100.0%) | |
| Bilateral | 4/10 (40.0%) | 0/5 (0.0%) | |
| rASRM score a | 78.5 ± 41.3 | 33.6 ± 8.9 | .053 |
| rASRM stage b | .119 | ||
| III | 3/10 (30.0%) | 4/5 (80.0%) | |
| IV | 7/10 (70.0%) | 1/5 (20.0%) | |
| Preoperative laboratory findings | |||
| WBC a | 9596 ± 6160 | 5978 ± 2259 | .254 |
| CRP a | 2.70 ± 5.25 | 0.03 ± 0.04 | .024 |
| Neutrophil to lymphocyte ratio a | 4.5 ± 3.2 | 1.8 ± 0.4 | .099 |
| Fever b | 4/10 (40.0%) | 0/5 (0%) | .231 |
a
Wilcoxon exact rank test.
b
Fisher exact test.